{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:31:14Z","timestamp":1791304274125,"version":"4.3.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatment, and preliminary evidence of efficacy of the scheduled drug for the particular condition. Since 2014, the authors have obtained 50 licenses on a case-by-case basis and developed a psychedelic-assisted group therapy model utilizing MDMA and LSD. The majority of the patients taking part in the psychedelic group therapy suffered from chronic complex post-traumatic stress disorder (c-PTSD), dissociative, and other post-traumatic disorders. Treatment modalities, typical developments and problems encountered during and after the psychedelic experiences are described. Recurrent depression poses a frequent problem, and requires special attention. Symptoms of c-PTSD predominantly addressed by the psychedelic experiences are the regulation of emotions and impulses, negative self-perception, alterations in relationships to others, as well as meaning, recall, and processing of traumatic memories. C-PTSD needs a larger number of psychedelic experiences in contrast to PTSD resulting from single trauma. In this model MDMA was most often used in the first phase to enhance motivation to change, strengthen the therapeutic alliance, allowing it to become more resilient, stress-relieved and less ambivalent. When emotional self-regulation, negative self-perception and structural dissociation had also begun to improve and trauma exposure was better tolerated, LSD was introduced to intensify and deepen the therapeutic process. The majority of participants improved by clinical judgement, and no serious adverse events occurred. A short case vignette describes a typical process. The experiences with this model can serve to further develop the method of psychedelic-assisted psychotherapy (PAP) and to give directions for future research.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.863552","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T06:18:02Z","timestamp":1650867482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":63,"title":["Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"Peter","family":"Oehen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/02791072.1985.10524332","article-title":"LSD in the supportive care of the terminally ill cancer patient","volume":"17","author":"Kurland","year":"1985","journal-title":"J Psychoactive Drugs."},{"key":"B2","article-title":"Thirty years of psychedelic research: the Spring Grove experiment and its sequels","volume-title":"Unpublished Manuscript, Based on an Address to the European College of Consciousness (ECBS) International Congress in Goettingen, Germany.","author":"Yensen","year":"1992"},{"key":"B3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol."},{"key":"B4","volume-title":"Halluzinogene","author":"Leuner","year":"1981"},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00115-005-2001-y","article-title":"Zur Fruehgeschichte von Ecstasy","volume":"77","author":"Benzenhoefer","year":"2006","journal-title":"Nervenarzt."},{"key":"B11","unstructured":"2017"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psycho-Pharmacology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymetham-phetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"B17","first-page":"59Y65","article-title":"Die Psycholytische Therapie in der Schweiz von 1988-1993","volume":"147","author":"Gasser","year":"1996","journal-title":"Schweiz Arch Neurol Psychol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine."},{"key":"B19","unstructured":"2020"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2021_268","article-title":"Psychedelic group therapy","author":"Gasser","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"B21","volume-title":"The Haunted Self: Structural Dissociation and the Treatment of Chronic Traumatization (Norton Series on Interpersonal Neurobiology)","author":"Van der Hart","year":"2006"},{"key":"B22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"Maclean","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jts.2490050305","article-title":"Complex PTSD","volume":"5","author":"Herman","year":"1992","journal-title":"J Traumatic Stress."},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5498\/wjp.v8.i1.12","article-title":"Complex posttraumatic stress disorder: the need to consolidate a distinct clinical syndrome or to reevaluate features of psychiatric disorders following interpersonal trauma","volume":"8","author":"Giourou","year":"2018","journal-title":"World J Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1418103","DOI":"10.1080\/20008198.2017.1418103","article-title":"PTSD and Complex PTSD: ICD-11 updates on concept and measure-ment in the UK, USA, Germany and Lithuania","volume":"8","author":"Karatzias","year":"2018","journal-title":"Eur J Psychotraumatol."},{"key":"B28","unstructured":"2012"},{"key":"B29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jts.20697","article-title":"Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices","volume":"24","author":"Cloitre","year":"2011","journal-title":"J Trauma Stress."},{"key":"B30","doi-asserted-by":"publisher","first-page":"28186","DOI":"10.3402\/ejpt.v6.28186","article-title":"Psychotherapies for PTSD: what do they have in common?","volume":"6","author":"Schnyder","year":"2015","journal-title":"Eur J Psychotrauma-tol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fpsyg.2017.01238","article-title":"Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions","volume":"8","author":"Barrett","year":"2017","journal-title":"Front Psychol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology."},{"key":"B33","volume-title":"Good Vibrations \u2013 Die heilende Kraft der Musik","author":"Koelsch","year":"2019"},{"key":"B34","volume-title":"Stille","author":"Kagge","year":"2016"},{"key":"B35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/0269881120959604","article-title":"Acute subjective effects in MDMA- and LSD-assisted psychotherapy","volume":"35","author":"Schmid","year":"2021","journal-title":"J Psychopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00213-020-05710-w","article-title":"Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy","volume":"238","author":"Feduccia","year":"2021","journal-title":"Psychopharmacology."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.863552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T06:18:10Z","timestamp":1650867490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.863552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":36,"alternative-id":["10.3389\/fpsyt.2022.863552"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.863552","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"863552"}}